Novexel Appoints Chief Financial Officer
News Jan 23, 2006
Novexel has announced the appointment of Gordon Waldron as Chief Financial Officer with immediate effect.
Gordon joins Novexel from the French biotechnology company Synt:em S.A., where he held the position of Vice President Finance & CFO from 1997.
During this time he built a pan-European, blue chip investor base, raised €30 million in private equity financing, negotiated a technology out licensing deal with a US public biotech company and ultimately the sale of Synt:em to a private French pharmaceutical company.
Prior to Synt:em, Gordon was Group Finance Manager for Europe, Africa and Middle East at Texas Instruments Software in the UK, which involved Group Financial and Management Accounting for 17 legal entities and a distributor network across 14 countries.
During this time, Gordon participated in negotiations for various MBO/entity disposal projects.
Gordon also worked for the Paris branch of Texas Instruments Software where he was Finance Director of their start-up subsidiary.
Previously, Gordon held Controller positions at Spie Batignolles in both the US and France.
Iain Buchanan, CEO of Novexel, commented, "I am delighted to welcome Gordon to Novexel in this key role. His breadth of financial experience will be of tremendous value as we continue to build the Company in 2006 and beyond."
Lab Innovations returns to the NEC, Bimingham , UKNews
Save the date for the UK’s only lab-dedicated exhibition showcase!READ MORE
PhoreMost Completes $15M (£11M) Series-A Round to Enter Drug DiscoveryNews
Investment to fund expansion of operations and progression of drug target pipeline.READ MORE
Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing SitesNews
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.READ MORE
Comments | 0 ADD COMMENT
International Conference on Biobetters and Regulatory Affairs
Jun 27 - Jun 28, 2018